Maleimides
"Maleimides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D008301
|
MeSH Number(s) |
D02.241.081.337.502.524 D02.478.440 D03.383.129.578.399
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Maleimides".
Below are MeSH descriptors whose meaning is more specific than "Maleimides".
This graph shows the total number of publications written about "Maleimides" by people in this website by year, and whether "Maleimides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 0 | 2 | 2 | 1999 | 0 | 2 | 2 | 2000 | 0 | 4 | 4 | 2002 | 1 | 0 | 1 | 2003 | 0 | 2 | 2 | 2005 | 1 | 0 | 1 | 2006 | 0 | 1 | 1 | 2007 | 1 | 0 | 1 | 2008 | 0 | 1 | 1 | 2009 | 0 | 3 | 3 | 2011 | 1 | 0 | 1 | 2012 | 1 | 1 | 2 | 2013 | 0 | 1 | 1 | 2016 | 1 | 0 | 1 | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Maleimides" by people in Profiles.
-
Gupta Y, Maciorowski D, Zak SE, Jones KA, Kathayat RS, Azizi SA, Mathur R, Pearce CM, Ilc DJ, Husein H, Herbert AS, Bharti A, Rathi B, Durvasula R, Becker DP, Dickinson BC, Dye JM, Kempaiah P. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays. Methods. 2021 11; 195:57-71.
-
Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, Cryns VL, Mazar AP. GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer Lett. 2016 10 01; 380(2):384-392.
-
Rizzieri DA, Cooley S, Odenike O, Moonan L, Chow KH, Jackson K, Wang X, Brail L, Borthakur G. An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. Leuk Lymphoma. 2016 08; 57(8):1800-6.
-
Kong Y, Zhang H, Chen X, Zhang W, Zhao C, Wang N, Wu N, He Y, Nan G, Zhang H, Wen S, Deng F, Liao Z, Wu D, Zhang J, Qin X, Haydon RC, Luu HH, He TC, Zhou L. Destabilization of heterologous proteins mediated by the GSK3ß phosphorylation domain of the ß-catenin protein. Cell Physiol Biochem. 2013; 32(5):1187-99.
-
Budke B, Kalin JH, Pawlowski M, Zelivianskaia AS, Wu M, Kozikowski AP, Connell PP. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity. J Med Chem. 2013 Jan 10; 56(1):254-63.
-
Kubic JD, Mascarenhas JB, Iizuka T, Wolfgeher D, Lang D. GSK-3 promotes cell survival, growth, and PAX3 levels in human melanoma cells. Mol Cancer Res. 2012 Aug; 10(8):1065-76.
-
Sirsi SR, Hernandez SL, Zielinski L, Blomback H, Koubaa A, Synder M, Homma S, Kandel JJ, Yamashiro DJ, Borden MA. Polyplex-microbubble hybrids for ultrasound-guided plasmid DNA delivery to solid tumors. J Control Release. 2012 Jan 30; 157(2):224-34.
-
Bourseau-Guilmain E, Béjaud J, Griveau A, Lautram N, Hindré F, Weyland M, Benoit JP, Garcion E. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int J Pharm. 2012 Feb 14; 423(1):93-101.
-
Mukherjee S, Dhar R, Das AK. Analyzing the catalytic mechanism of protein tyrosine phosphatase PtpB from Staphylococcus aureus through site-directed mutagenesis. Int J Biol Macromol. 2009 Dec 01; 45(5):463-9.
-
Numano R, Szobota S, Lau AY, Gorostiza P, Volgraf M, Roux B, Trauner D, Isacoff EY. Nanosculpting reversed wavelength sensitivity into a photoswitchable iGluR. Proc Natl Acad Sci U S A. 2009 Apr 21; 106(16):6814-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|